BioDiscovery : Conference Abstract
|
Corresponding author: Simona Collina (simona.collina@unipv.it)
Received: 16 Jun 2017 | Published: 05 Jul 2017
© 2017 Simona Collina, Marta Rui, Giacomo Rossino, Serena Della Volpe, Daniela Rossi, Arianna Scuteri, Alessio Malacrida, Guido Cavaletti
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Citation: Collina S, Rui M, Rossino G, Della Volpe S, Rossi D, Scuteri A, Malacrida A, Cavaletti G (2017) Sigma 1 receptor modulators as a new weapon against multiple sclerosis. BioDiscovery 20: e14565. https://doi.org/10.3897/biodiscovery.20.e14565
|
|
Multiple Sclerosis (MS) is a disabling immune-mediated neurological disease, affecting more than 2.5 million people worldwide. Regardless of the broad arena of pharmaceutical strategies against MS, up to now a concrete cure is still missing. The drugs against MS currently used in the clinical practice are mainly biological immunomodulatory therapeutics, which are effective and safe during the short-term treatment. Nevertheless, they are suitable only for systemic administration and fairly expensive, hence academic and industrial environments are still addressing their efforts towards the development of new drugs
During the years, our interdisciplinary research group identified compound (R)-RC-33, as a new selective S1R agonist with an excellent S1R affinity (Ki= 1.8 nM) along with high selectivity over other receptors, including S2R, and good in vitro metabolic stability
Sigma 1 receptors, Multiple Sclerosis, (R)-RC-33
Simona Collina
Word BioDiscovery Congress 2017